Background Medium vessel occlusions (MeVOs) account for 25–40% of acute ischemic stroke. The Tenzing 5 (Route 92 Medical, San Mateo, California, USA) and FreeClimb 54 (Route 92 Medical, San Mateo, ...

Real-World U.S. Physician Preference Data1 Demonstrates the SOFIA™ 88 Catheter's Trackability, Atraumatic Design, and Overall Performance in Stroke Procedures NASHVILLE, Tenn., July 14, 2025 ...

Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 ...

Terumo Neuro Unveils New SOFIA™ 88 Catheter Data Demonstrating Strong Performance Compared to Other Super-Bore Catheters Provided by PR Newswire Jul 14, 2025, 6:00:00 AM ...

"These real-world results further validate SOFIATM 88 catheter's position as a leading super-bore support catheter," said Carsten Schroeder, President and CEO of Terumo Neuro. "This new dataset ...

/PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the commercial ...

Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships.

Terumo Neuro's SOFIA ™ Catheter Line is Backed By 10 Years of Proven Clinical Performance1-9 and Innovation – The New SOFIA™ Flow 88 Offers Reliable Trackability, Proximal Stability and ...